SCHEMBL3948570

SCHEMBL3948570

O=CCCCC1CCNCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITGB3 P05106 3/20 0.39
▸ ITGA2B P08514 3/20 0.39
▸ HRH3 Q9Y5N1 2/20 0.39
▸ HIF1A Q16665 1/20 0.38
▸ SLC6A1 P30531 2/20 0.36
▸ GABRA5 P31644 2/20 0.36
▸ GABRB2 P47870 2/20 0.36
▸ SLC6A12 P48065 2/20 0.36
▸ SLC6A11 P48066 2/20 0.36
▸ SLC6A13 Q9NSD5 2/20 0.36
▸ FAAH O00519 1/20 0.36
▸ GABRA1 P14867 1/20 0.36
▸ GABRR1 P24046 1/20 0.36
▸ GABRA4 P48169 1/20 0.36
▸ GNAO1 P09471 3/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ TPSAB1 Q15661 1/20 0.35
▸ TPSD1 Q9BZJ3 1/20 0.35
▸ TPSG1 Q9NRR2 1/20 0.35
▸ GNAI3 P08754 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2409711 0.86 GABRA5 (0.43) ITGB3ITGA2BHRH3SLC6A1GABRA5
SCHEMBL4578412 0.84 — —
SCHEMBL8741893 0.83 ITGB3 (0.36) ITGB3ITGA2BHRH3SLC6A1GABRA5
SCHEMBL7357879 0.82 SLC6A1 (0.46) ITGB3ITGA2BHRH3HIF1ASLC6A1
SCHEMBL2076622 0.79 CYP1A2 (0.46) HIF1ATSHR
SCHEMBL8944666 0.79 — —
SCHEMBL13673452 0.78 HRH3 (0.39) ITGB3ITGA2BHRH3FAAHGNAO1
SCHEMBL237382 0.78 ITGB3 (0.47) ITGB3ITGA2BHRH3SLC6A1GABRA5
SCHEMBL331124 0.78 HRH3 (0.47) ITGB3ITGA2BHRH3SLC6A1GABRA5
SCHEMBL3956314 0.78 GNAI3 (0.42) ITGB3ITGA2BHRH3SLC6A1GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11446398-B2 Regulated biocircuit systems OBSIDIAN THERAPEUTICS, INC. (US) 2022-09-20 — — US disclosed
US-20210254056-A1 IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS CAMP4 THERAPEUTICS CORPORATION 2021-08-19 — — US disclosed
WO-2009024825-A1 2-PYRAZINYLBENZIMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS ASTRAZENECA AB (SE) 2009-02-26 — — WO disclosed
EP-0693067-B1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2000-01-12 — — EP disclosed
EP-0664792-B1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2000-01-05 — — EP disclosed
EP-0478362-B1 Fibrinogen receptor antagonists MERCK & CO INC (US) 1999-06-09 — — EP disclosed
EP-0512829-B1 Fibrinogen receptor antagonists MERCK & CO INC (US) 1998-03-04 — — EP disclosed
US-5721253-A Fibrinogen receptor antagonists MERCK & CO., INC. (US) 1998-02-24 — — US disclosed
US-5652247-A VASOPRESSIN ANTAGONIST OTSUKA PHARMACEUTICAL CO., LTD (JP) 1997-07-29 — — US disclosed
EP-0664792-A4 FIBRINOGEN RECEPTOR ANTAGONISTS. MERCK & CO INC (US) 1996-09-25 — — EP disclosed
US-5272158-A Fibrinogen receptor antagonists MERCK & CO., INC. (US) 1993-12-21 — — US disclosed
US-5264420-A Anticoagulants MERCK & CO., INC. (US) 1993-11-23 — — US disclosed
US-5225402-A Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-07-06 — — US disclosed
EP-0540334-A1 Fibrinogen receptor antagonists MERCK & CO. INC. (US) 1993-05-05 — — EP disclosed
EP-0512829-A1 Fibrinogen receptor antagonists MERCK & CO. INC. (US) 1992-11-11 — — EP disclosed
CN-1060293-A Fibrinogen receptor anlagonists MERCK & CO INC (US) 1992-04-15 — — CN disclosed
EP-0479481-A2 Fibrinogen receptor antagonists MERCK & CO. INC. (US) 1992-04-08 — — EP disclosed
CN-1060096-A FIBRINOGEN RECEPTOR ANLAGONISTS MERCK & CO INC (US) 1992-04-08 — — CN disclosed
EP-0478362-A2 Fibrinogen receptor antagonists MERCK & CO. INC. (US) 1992-04-01 — — EP disclosed
CN-1046529-A Carbostyril derivative OTSUKA PHARMA CO LTD (JP) 1990-10-31 — — CN disclosed
Send feedback